echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Cinda Bio-PD-1 and Ipilimumab-like drugs are approved for clinical use in nasopharyngeal carcinoma

    Cinda Bio-PD-1 and Ipilimumab-like drugs are approved for clinical use in nasopharyngeal carcinoma

    • Last Update: 2021-08-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On July 20, Innovent's Ipilimumab biosimilar drug IBI310 and its PD-1 monoclonal antibody Sintilizumab were approved for use in nasopharyngeal cancer IND applications


    Currently, according to the Insight database, Cinda has carried out 6 clinical trials of IBI310 combined with Sintilimab in China for hepatocellular carcinoma, cervical cancer, postoperative adjuvant melanoma, and dMMR/MSI-H advanced colorectal cancer


    Development of clinical trials of Sintilimab combined with IBI310

    From the Insight database (http://db.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.